Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease

Annals of Pharmacotherapy

Volumn 41, Issue 11, 2007, Pages 1761-1769

  Maddux, Franklin W ^a   Shetty, Sharashchandra ^b   Del Aguila, Michael A ^c   Nelson, Michael A ^d   Murray, Brian M ^e  

^a Specialty Care Services Group   (United States)

^b i3 Innovus   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d Health Economics and Outcomes Research   (United States)

^e ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; Darbepoetin alfa; Epoetin alfa; Erythropoiesis stimulating agents; Predialysis

Indexed keywords

ERYTHROPOIETIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; COST CONTROL; COST OF ILLNESS; DIALYSIS; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIESIS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HEMATINICS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 35748982914     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K194     Document Type: Article

References (33)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12. DOI 10.1052/ajkd.2003.50007
2. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20: 1501-10. DOI 10.1185/030079904X2763
3. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34.
4. Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol 2006;17:2293-8. Epub 12 Jul 2006. DOI 10.1681/ASN.2005020183
5. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006;69:560-4. DOI 10.1038/sj.ki.5000105
6. Lu WX, Jones-Burton C, Zhan M, Salzberg DJ, Moore J Jr, Fink JC. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract 2005;101:c79-86. DOI 10.1159/000086226
7. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18(suppl 2):ii2-6. DOI 10.1093/ndt/gfg1058
8. Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int 2002;62:229-36. DOI 10.1046/j.1523-1755.2002.00432.x
9. Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000;36:282-93.
10. Perkins R, Olson S, Hansen J, Lee J, Stiles K, Lebrun C. Impact of an anemia clinic on emergency room visits and hospitalizations in patients with anemia of CKD pre-dialysis. Nephrol Nurs J 2007;34:167-74.
11. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004;15:1300-6. DOI 10.1097/01.ASN.0000125670. 64996.BB
12. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol 2001;12:1713-20.
13. London R, Solis A, Goldberg GA, Wade S, Chan WW. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population. J Manag Care Pharm 2003;9:248-55.
14. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005(3):CD003266.
15. Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 2005;68:788-95. DOI 10.1111/j.1523-1755.2005. 00458.x
16. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-6.
17. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-12.
18. Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005;21:981-7. DOI 10.1185/030079905X49644
19. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-60.
20. National Kidney Foundation. National Kidney Foundation releases anemia guideline update: new recommendations based on months of analysis of six new randomized trials. www.kidney.org/news/newsroom/ newsitem.cfm?id=408 (accessed 2007 Aug 30).
21. Food and Drug Administration. Information for Healthcare Professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)], 2007. www.fda.gov/ cder/drug/Infosheets/HCP/ RHE2007HCP.htm (accessed 2007 Aug 30).
22. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
23. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
24. Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease. Dis Manag 2007;10:37-45.
25. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37: 348-55.
26. London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 2002;40:539-48. DOI 10.1053/ajkd.2002.34912
27. Hunsicker LG. The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol 2004;15:1363-4. DOI 10.1097/01.ASN.0000126069.68755.99
28. Kiberd B. The chronic kidney disease epidemic: stepping back and looking forward. J Am Soc Nephrol 2006;17:2967-73.
29. National Kidney Foundation - Kidney Early Evaluation Program. KEEP Annual Data Report 2006. Am J Kidney Dis 2007;49(3 suppl 3):S1-160.
30. Nitz NM, Jumadilova Z, Darkow T, Frytak JR, Bavendam T. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. Am J Manag Care 2005;11(4 suppl): S130-9.
31. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med 2007;356:959-61.
32. Bruns FJ, Seddon P, Saul M, Zeidel ML. The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. J Am Soc Nephrol 1998;9:884-90.
33. National Kidney Foundation. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;37(1 suppl 1):S182-238. DOI 10.1053/j.ajkd.2006.03.010